Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges.
暂无分享,去创建一个
[1] J. Ward,et al. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016 , 2017, MMWR. Morbidity and mortality weekly report.
[2] A. Gomaa,et al. Hepatitis C infection in Egypt: prevalence, impact and management strategies , 2017, Hepatic medicine : evidence and research.
[3] I. Waked,et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care , 2017, Journal of viral hepatitis.
[4] A. Fontanet,et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[5] J. Ward,et al. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. , 2016, MMWR. Morbidity and mortality weekly report.
[6] W. Doss,et al. Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. , 2016, Journal of advanced research.
[7] S. Alim,et al. Effect of Sofosbuvir, brand drug (Sovaldi) versus generic (MPIViropack) in treating Chronic HCV infection among Egyptian patients , 2015 .
[8] J. Ward,et al. Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015 , 2015, MMWR. Morbidity and mortality weekly report.
[9] H. Razavi,et al. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies , 2015, Alimentary pharmacology & therapeutics.
[10] M. Gogia. Assessing Risky Behavior of PWIDs in Georgia - Comparable Analyses of Two Samples , 2015 .
[11] F. Amer,et al. Epidemiology of Hepatitis C Virus Infection in Egypt. , 2015 .
[12] T. Elbaz,et al. New era for management of chronic hepatitis C virus using direct antiviral agents: A review , 2014, Journal of advanced research.
[13] P. André,et al. Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[14] del RioCarlos,et al. Mortality and Causes of Death Among HIV-Infected Individuals in the Country of Georgia: 1989–2012 , 2014 .
[15] H. Razavi,et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.
[16] B. Milani,et al. Pathway to affordable quality assured sources of pegylated interferon alpha for treating hepatitis C , 2013 .
[17] C. Treloar,et al. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] A. V. Burdakov,et al. Electronic integrated disease surveillance system and pathogen asset control system. , 2012, The Onderstepoort journal of veterinary research.
[19] M. Hassany,et al. The future for the treatment of genotype 4 chronic hepatitis C , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[20] Gamal Esmat,et al. Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. , 2012, MMWR. Morbidity and mortality weekly report.
[21] M. Topuridze,et al. Nosocomial Infections in Tbilisi, Georgia: A Retrospective Study of Microbiological Data from 4 Major Tertiary Care Hospitals , 2011, Infection Control & Hospital Epidemiology.
[22] L. Kostrikis,et al. Near-Full Genome Characterisation of Two Natural Intergenotypic 2k/1b Recombinant Hepatitis C Virus Isolates , 2011, Advances in virology.
[23] F. Sugauchi,et al. Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.
[24] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[25] I. Moreau,et al. Serendipitous identification of natural Intergenotypic recombinants of hepatitis C in Ireland , 2006, Virology Journal.
[26] F. Mahoney,et al. Evolution of infection control in Egypt: achievements and challenges. , 2006, American journal of infection control.
[27] K. Nelson,et al. Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A Population-Based Survey of the Adult Population of T'bilisi, Republic of Georgia , 2006, Journal of Urban Health.
[28] C. del Rio,et al. Risk Factors for Hepatitis C Virus Infection among Blood Donors in Georgia , 2003, European Journal of Epidemiology.
[29] F. Mahoney,et al. Overview of injection practices in two governorates in Egypt , 2003, Tropical medicine & international health : TM & IH.
[30] Malla R Rao,et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt , 2002, BMC infectious diseases.
[31] Olga Kalinina,et al. A Natural Intergenotypic Recombinant of Hepatitis C Virus Identified in St. Petersburg , 2002, Journal of Virology.
[32] F. Miller,et al. High HCV prevalence in Egyptian blood donors , 1992, The Lancet.